Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens

Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a “Trojan horse” active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms...

Descripción completa

Detalles Bibliográficos
Autor principal: Bonomo, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853757/
https://www.ncbi.nlm.nih.gov/pubmed/31724046
http://dx.doi.org/10.1093/cid/ciz823
_version_ 1783470093657702400
author Bonomo, Robert A
author_facet Bonomo, Robert A
author_sort Bonomo, Robert A
collection PubMed
description Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a “Trojan horse” active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases.
format Online
Article
Text
id pubmed-6853757
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68537572019-11-19 Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens Bonomo, Robert A Clin Infect Dis Supplement Articles Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a “Trojan horse” active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases. Oxford University Press 2019-12-01 2019-11-13 /pmc/articles/PMC6853757/ /pubmed/31724046 http://dx.doi.org/10.1093/cid/ciz823 Text en © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Articles
Bonomo, Robert A
Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
title Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
title_full Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
title_fullStr Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
title_full_unstemmed Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
title_short Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
title_sort cefiderocol: a novel siderophore cephalosporin defeating carbapenem-resistant pathogens
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853757/
https://www.ncbi.nlm.nih.gov/pubmed/31724046
http://dx.doi.org/10.1093/cid/ciz823
work_keys_str_mv AT bonomoroberta cefiderocolanovelsiderophorecephalosporindefeatingcarbapenemresistantpathogens

Ejemplares similares